What it's for (Indications)
- This topical medication, combining lignocaine, neomycin, and polymyxin B, is primarily indicated for the treatment and prevention of superficial bacterial infections of the skin.
- It is particularly useful for minor cuts, scrapes, abrasions, superficial burns, and other dermatological lesions that are susceptible to infection by susceptible Gram-positive and Gram-negative organisms.
- The inclusion of lignocaine provides symptomatic relief by acting as a local anesthetic, reducing pain and discomfort associated with these conditions.
- The broad-spectrum antibacterial components (neomycin and polymyxin B) target a range of common skin pathogens, helping to prevent infection and promote healing.
- It is crucial to limit its use to superficial infections and to areas without extensive skin damage to minimize systemic absorption and potential adverse effects.
- The use should always be under the guidance of a healthcare professional, ensuring appropriate duration of treatment to avoid resistance and other complications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | This medication is intended for external topical application only. A thin layer of the product should be applied gently to the clean, affected skin area one to three times daily, or as directed by a healthcare professional. The precise frequency and duration of treatment should be determined by the severity and extent of the infection, and the patient's clinical response. It is imperative to avoid applying this medication over large body surface areas, to extensive areas of broken, abraded, or denuded skin, or under occlusive dressings, as these practices can significantly increase systemic absorption of its active components, thereby heightening the risk of systemic adverse effects. The treatment course should generally be limited to avoid the potential for developing antibiotic resistance and minimizing exposure to potentially toxic systemic levels. Patients must strictly adhere to the dosing instructions provided by their physician or pharmacist and on the product labeling. |
Safety & Warnings
Common Side Effects
- Local side effects are the most commonly reported and can include irritation, redness (erythema), itching (pruritus), burning sensation, and rash at the application site.
- Allergic contact dermatitis, particularly a delayed hypersensitivity reaction to neomycin, is a well-recognized potential side effect, manifesting as erythema, scaling, pruritus, and blistering.
- Prolonged use or application over large areas, to broken skin, or in individuals with compromised renal function, can lead to significant systemic absorption of the active ingredients, increasing the risk of serious systemic adverse effects.
- Systemic absorption of neomycin is associated with irreversible ototoxicity (hearing loss, tinnitus, vestibular dysfunction) and nephrotoxicity (kidney damage).
- Polymyxin B, if systemically absorbed, can cause nephrotoxicity and neurotoxicity (e.
- g.
- , paresthesia, dizziness, ataxia).
- Lignocaine systemic absorption can lead to central nervous system effects such as lightheadedness, dizziness, nervousness, drowsiness, confusion, blurred vision, tremors, and seizures, as well as cardiovascular effects including bradycardia, hypotension, and potentially cardiac arrest.
- Patients should immediately report any severe or persistent local reactions or any signs of systemic adverse effects to a healthcare provider.
Serious Warnings
- Black Box Warning: **SERIOUS SYSTEMIC TOXICITY FROM TOPICAL ABSORPTION.** Although intended for topical application, significant systemic absorption of lignocaine, neomycin, and polymyxin B can occur, particularly when this product is applied over large body surface areas, to denuded or compromised skin (e.g., severe burns, extensive wounds), for prolonged durations, or under occlusive dressings. Systemic absorption of **Neomycin** carries a substantial risk of irreversible ototoxicity, manifesting as hearing loss, tinnitus, and vestibular dysfunction, and nephrotoxicity (kidney damage), especially in patients with pre-existing renal dysfunction or when co-administered with other known nephrotoxic or ototoxic drugs. Similarly, systemic absorption of **Polymyxin B** can lead to nephrotoxicity and neurotoxicity, which may include peripheral neuropathy (e.g., paresthesia, numbness) and potentially respiratory paralysis. Systemic absorption of **Lignocaine** can result in severe central nervous system effects, including lightheadedness, dizziness, nervousness, drowsiness, tremors, confusion, and seizures, as well as significant cardiovascular depression, which can manifest as bradycardia, hypotension, and even cardiac arrest. Therefore, patients must be carefully monitored for any signs or symptoms of systemic toxicity. Discontinue use immediately if any signs of systemic adverse reactions occur. This product is strictly not for ophthalmic use, nor for intra-auricular use in the presence of a perforated tympanic membrane, or for application on extensive burns or deep, penetrating wounds due to the increased systemic risks. The potential benefits must be critically weighed against these severe potential risks before administration.
- This product is for external use only and must not be used in the eyes, ingested, or applied into the ear canal if the tympanic membrane is perforated, due to the risk of ototoxicity.
- Prolonged use of this antibiotic combination may result in the overgrowth of non-susceptible organisms, including fungi, necessitating re-evaluation of treatment.
- Patients should discontinue use and consult a physician if irritation, sensitization (e.
- g.
- , increased redness, swelling, itching), or superinfection occurs or worsens, or if the initial infection does not show improvement.
- There is a potential for cross-sensitization among aminoglycoside antibiotics.
- Extreme caution must be exercised when applying this medication to large body surface areas, to areas with compromised skin integrity (e.
- g.
- , extensive burns, deep wounds), or under occlusive dressings, as these conditions significantly enhance systemic absorption of lignocaine, neomycin, and polymyxin B.
- Such increased absorption elevates the risk of severe systemic toxicities, including ototoxicity, nephrotoxicity, and central nervous system/cardiovascular effects.
- Regular monitoring of renal function and auditory status may be necessary if significant systemic absorption is suspected or unavoidable.
- Avoid concomitant use with other nephrotoxic or ototoxic medications if systemic absorption is anticipated.
How it Works (Mechanism of Action)
The therapeutic efficacy of this combination drug is derived from the distinct yet complementary mechanisms of action of its three active components. **Lignocaine (Lidocaine)**, an amide-type local anesthetic, works by reversibly blocking voltage-gated sodium channels in the neuronal membrane. By inhibiting the rapid influx of sodium ions required for depolarization and action potential generation, lignocaine prevents the initiation and conduction of nerve impulses, thereby providing localized anesthesia and pain relief. Its action is non-selective, affecting sensory, motor, and autonomic nerve fibers. **Neomycin**, an aminoglycoside antibiotic, exerts its bactericidal effect by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This binding interferes with protein synthesis by causing misreading of mRNA, leading to the incorporation of incorrect amino acids into bacterial proteins. The resulting abnormal or non-functional proteins disrupt essential cellular processes, ultimately causing bacterial cell death. Neomycin is effective against a broad spectrum of Gram-negative aerobic bacteria and certain Gram-positive organisms. **Polymyxin B**, a cyclic polypeptide antibiotic, acts primarily on the outer membrane of Gram-negative bacteria, particularly *Pseudomonas aeruginosa*. It behaves as a cationic detergent, binding to the negatively charged lipopolysaccharide (LPS) components of the bacterial outer membrane. This binding disrupts the membrane's integrity, leading to increased permeability, leakage of intracellular contents (e.g., ions, metabolites), and subsequent bacterial cell lysis and death. The synergistic combination offers comprehensive antimicrobial coverage complemented by effective pain management for superficial infections.
Commercial Brands (Alternatives)
No other brands found for this formula.